

YTD 2025 China Out-Licensing Deals

Licensors	Licensee	Date	Asset(s)	Target + Modality	Deal Phase	TA
		2/19/2025	SYS6005	ROR1 ADC	Phase 1	Oncology
		2/18/2025	HPB-143	IRAK4 PROTAC	IND	I&I
		1/22/2025	MRG007	Unknown ADC	Preclinical	Oncology
 	Prolium Biosciences	1/20/2025	CM355	CD20 x CD3 Bispecific Antibody	Phase 1/2	Oncology
		1/14/2025	GFH375	KRAS G12D Small Molecule	Phase 1/2	Oncology
		1/13/2025	SCR-8572	CD3 x GPR x C5D x BCMA Trispecific Antibody	Phase 1	Oncology
		1/13/2025	GR1017 + up to 18 ADCs against specific targets	FGFR3 ADC	Preclinical	Oncology
 	Windward Bio	1/10/2025	HBM9378	TSLP mAb	Phase 1	I&I
 	Johnson&Johnson	1/10/2025	Undisclosed	BTK Degraders	Preclinical	Multiple
		1/10/2025	CM313	CD38 mAb	Phase 2	I&I / Oncology
		1/9/2025	SOT109	Unknown ADC	Preclinical	Oncology
		1/9/2025	XW004 & VRB-103	GLP-1 / GLP-1R Peptide & Amylin Peptide	Phase 1 & Preclinical	CV / Metabolic
		1/9/2025	MIL116	APRIL mAb	Preclinical	I&I
		1/7/2025	Undisclosed	CD19 x CD20 x CD3 Trispecific Antibody	Preclinical	I&I
		1/7/2025	DB-1418	HER3 x EGFR ADC / Bispecific Antibody	Preclinical	Oncology
		1/2/2025	IBI3009	DLL3 ADC	Phase 1	Oncology

Note: innovative assets only (no biosimilars); assets only (not just platform technology); must include major ex-China markets (i.e. US, EU, Japan)
Note: Ouro Medicines licensed CM336 in November 2024 through subsidiary Platina Medicines
As of 2/23/2025